Therapeutic Approach

Archive: 2020

Ritter Pharmaceuticals, Inc. Announces Adjournment of its Special Meeting

Ritter Pharmaceuticals, Inc. Announces Adjournment of its Special Meeting LOS ANGELES (May 14, 2020) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter” or the “Company”), today announced at it has adjourned its special meeting of stockholders, originally scheduled for today, until Monday, May 18, 2020 at 12:00 p.m., Pacific Time. The special meeting was adjourned to […]

Leave Your Comments »

Ritter Pharmaceuticals Regains Compliance with Nasdaq’s Stockholders’ Equity Requirement for Continued Listing

Ritter Pharmaceuticals Regains Compliance with Nasdaq’s Stockholders’ Equity Requirement for Continued Listing  LOS ANGELES (May 11, 2020) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), today announced that it has received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq’s stockholders’ equity requirement for continued […]

Leave Your Comments »

Leading Independent Proxy Advisory Firms Recommend Ritter Pharmaceuticals Shareholders Vote in Favor of its Merger and Each of the Merger Proposals

Leading Independent Proxy Advisory Firms Recommend Ritter Pharmaceuticals Shareholders Vote in Favor of its Merger and Each of the Merger Proposals  LOS ANGELES (May 6, 2020) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), today announced that Institutional Shareholder Services Inc. (ISS) and Glass Lewis, two leading independent research and proxy advisory […]

Leave Your Comments »

Ritter Pharmaceuticals Reports Financial Results for the First Quarter Ended March 31, 2020

Form S-4 Declared Effective by the SEC and Ritter/Qualigen Merger Voting is Underway LOS ANGELES (May 1, 2020) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”, Ritter” or the “Company”), a developer of therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, today reported financial results for the first quarter ended March 31, […]

Leave Your Comments »

Ritter Pharmaceuticals, Inc. Urges Stockholders to Vote Now on Proposed Merger with Biotech Company, Qualigen Inc.

  The merger CANNOT be consummated without the approval of EACH of the proposals being voted on at the Special Meeting, including approval of a reverse stock split. LOS ANGELES (April 28, 2020) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”, “Ritter” or the “Company”), is urging its stockholders to vote now on the proposed merger […]

Leave Your Comments »

Ritter Pharmaceuticals, Inc. Stockholders to Vote on Proposed Merger, Special Meeting Scheduled for May 14, 2020

Ritter Pharmaceuticals, Inc. Announces Form S-4 Registration Statement Declared Effective by SEC LOS ANGELES (April 16, 2020) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”, Ritter” or the “Company”), a developer of therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, today announced that the U.S. Securities and Exchange Commission (the “SEC”) has […]

Leave Your Comments »

Ritter Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2019

Definitive merger agreement with Qualigen, Inc. announced in January 2020 LOS ANGELES (March 31, 2020) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”, Ritter” or the “Company”), a developer of therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, today reported financial results for the fourth quarter and year ended December 31, 2019. […]

Leave Your Comments »

Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce Merger Agreement

Transaction to Create a Nasdaq-listed Biotechnology Company Focused on Advancing Qualigen’s Cancer and Infectious Disease Therapeutic Development Programs LOS ANGELES (January 21, 2020) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, reported that it has entered into a […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD